Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Mol Imaging Biol. 2019 Aug;21(4):705–712. doi: 10.1007/s11307-018-1288-6

Fig. 4:

Fig. 4:

In vivo biodistribution, specificity and pharmacokinetics of [18F]FE-OTS964. a Representative data of gamma-counting biodistribution analysis of mice injected with 71–141 uCi [18F]FE-OTS964 (unblocked, black bars) or 51–60 μCi [18F]FEOTS964 + 5 mg/kg OTS514 (blocked, red bars). b In vivo blood half-life of [18F]FE-OTS964 in NSG mice. *Significant at p<0.05, **significant at p<0.005.